Every 10-Q that Lantern Pharma Inc. (LTRN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LTRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LTRN filings page.
Lantern Pharma is an A.I.-driven oncology company with three clinical-stage small-molecule candidates (LP-300, LP-184/STAR-001, LP-284) and an ADC program, built around its RADR® and withZeta/Open-Medicine AI platforms. For the quarter ended June 30, 2026, it reported a net loss of $7.1 million versus $4.3 million a year earlier; the six‑month net loss was $10.4 million versus $8.9 million. Operating expenses fell as research and development dropped to $3.5 million for the first half of 2026 from $6.3 million, while general and administrative expenses rose modestly to $3.4 million.
Cash and cash equivalents were $6.7 million and marketable securities $0.7 million, with total assets of $8.6 million and a stockholders’ deficit of $3.2 million, driven largely by a new $7.5 million warrant liability. A May 2026 registered direct offering and concurrent private placement generated about $4.4 million of gross proceeds but also produced a non‑cash loss on warrant issuance and ongoing fair value remeasurement charges. Management discloses substantial doubt about the company’s ability to continue as a going concern without significant additional funding and plans to seek further capital, including via its ATM facility, collaborations, and grants, while continuing to progress its oncology and AI initiatives.
Lantern Pharma reported a Q1 2026 net loss of $3.33 million, narrower than the $4.54 million loss a year earlier, as research and development spending fell to $1.72 million from $3.26 million. General and administrative costs rose modestly to $1.68 million.
Cash, cash equivalents and marketable securities totaled about $6.3 million as of March 31, 2026, with working capital of roughly $3.28 million. The company discloses “substantial doubt” about its ability to continue as a going concern without significant additional funding.
After quarter-end, Lantern raised gross proceeds of approximately $4.4 million through a registered direct equity offering and concurrent private warrants, and now estimates its liquidity will fund operations until around the middle of the first quarter of 2027. Lantern also plans to spin out its withZeta.ai AI platform into an independent, potentially publicly listed entity to pursue dedicated funding separate from its core oncology drug development programs.
Lantern Pharma (LTRN) filed its Q3 2025 10‑Q, reporting a net loss of $4,177,423 for the quarter and $13,045,221 for the nine months ended September 30, 2025. Operating expenses fell year over year as research and development declined to $2,436,971 in Q3 (from $3,716,646), while general and administrative rose to $1,912,829. Interest income was $100,921 and other income, net was $71,456.
Cash and cash equivalents were $8,389,486 and marketable securities were $3,973,090 at September 30, 2025. Working capital was approximately $9,421,000. Management states that existing cash, cash equivalents, and marketable securities are expected to fund operations until approximately late June 2026 to mid August 2026, and the filing raises “substantial doubt” about the company’s ability to continue as a going concern without substantial additional funding.
To bolster liquidity, Lantern entered an at‑the‑market program of up to $15,530,000. In Q3, it sold 212,444 shares for gross proceeds of $989,061 and paid $29,672 in commissions; from October 1 to the report date, it sold an additional 144,204 shares for gross proceeds of $634,333, with $19,030 in commissions.
Lantern Pharma Inc. (LTRN) reported continuing operating losses as it advances three clinical-stage small-molecule candidates and an ADC program while relying on its RADR® A.I. platform. For the six months ended June 30, 2025, the company recorded a net loss of $8,867,798 versus $10,400,316 a year earlier, and net loss per share of $0.82 versus $0.97. Cash and cash equivalents were $6,061,408 and marketable securities were $9,840,366, giving approximately $15.9 million of combined liquidity and working capital of about $12.3 million.
The company noted a substantial doubt about its ability to continue as a going concern absent additional financing but expects existing resources to fund operations into June 2026. In July 2025 Lantern entered an ATM Sales Agreement to offer up to $15.53 million of common stock and sold 15,185 shares for approximately $80,000 through August 12, 2025. Research and development expense decreased to $6.33 million for the six months ended June 30, 2025 from $8.14 million a year earlier, while general and administrative expense was roughly stable at about $3.09 million. The company continues active clinical programs for LP-300 (Phase 2), LP-184 (Phase 1) and LP-284 (Phase 1) and operates the RADR platform and a Starlight subsidiary for CNS development.